tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Dec 28;24(1):1470.
doi: 10.1186/s12879-024-10345-9. Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco
Karima Abounouh[SUP] 1 [/SUP], Raji Tajudeen[SUP] 2 [/SUP], Hind Majidi[SUP] 3 [/SUP], Soad Redwane[SUP] 4 [/SUP], Oumaima Laazaazia[SUP] 1 [/SUP], Safaa Aqillouch[SUP] 1 [/SUP], Ahmed E Ogwell Ouma[SUP] 2 [/SUP], Mohammed Abdulaziz[SUP] 2 [/SUP], Merawi Aragaw[SUP] 2 [/SUP], Mosoka Papa Fallah[SUP] 2 [/SUP], Senga Sembuche[SUP] 2 [/SUP], Serge Batcho[SUP] 2 [/SUP], Patrick Kabwe[SUP] 2 [/SUP], Elizabeth Gonese[SUP] 2 [/SUP], Abdelhakim Ainahi[SUP] 5 [/SUP], M'hammed Sarih[SUP] 6 [/SUP], Jean Kaseya[SUP] #[/SUP][SUP] 2 [/SUP], Abderrahmane Maaroufi[SUP] #[/SUP][SUP] 1 [/SUP], Sayeh Ezzikouri[SUP] #[/SUP][SUP] 7 [/SUP]
Affiliations
To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument. Adjusted seroprevalence of anti-RBD antibodies showed that participants who received two doses of ChAdOx1-S followed by a BBIBP-CorV booster had a seroprevalence rate of 99.68% (95% CI: 99.39-99.83%), while those who received a BNT162b2 booster had a rate of 99.67% (95% CI: 99.38-99.82%). Both rates were higher than those observed with other vaccination regimens. The evaluation of booster dose effects revealed significant differences in anti-RBD antibody levels across various vaccination regimens: two doses of BBIBP-CorV compared to three doses of BBIBP-CorV (P < 0.0001), two doses of BNT162b2 versus three doses of BNT162b2 (P = 0.023), two doses of ChAdOx1-S versus two doses of ChAdOx1-S with a BNT162b2 booster (P = 0.023), and two doses of BBIBP-CorV versus two doses of BBIBP-CorV with a BNT162b2 booster (P < 0.0001). However, no significant difference was found between two doses of ChAdOx1-S and three doses of ChAdOx1-S (P = 0.23). Participants with prior SARS-CoV-2 exposure who received two doses of ChAdOx1-S followed by either a BBIBP-CorV or BNT162b2 booster showed higher levels of anti-RBD IgG antibodies (P = 0.042 and P = 0.001, respectively). Interestingly, individuals with comorbidities who received the BNT162b2 booster dose exhibited a significantly stronger humoral response (P < 0.05). In conclusion, our findings highlight the effectiveness of the BNT162b2 booster dose in eliciting a strong immune response. The high seroprevalence rates achieved with both BNT162b2 and BBIBP-CorV boosters reflect the country's robust vaccination strategy.
Keywords: 3 doses, Vaccines; Anti-RBD; COVID-19; Humoral response; SARS-CoV-2; Seroprevalence.
. 2024 Dec 28;24(1):1470.
doi: 10.1186/s12879-024-10345-9. Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco
Karima Abounouh[SUP] 1 [/SUP], Raji Tajudeen[SUP] 2 [/SUP], Hind Majidi[SUP] 3 [/SUP], Soad Redwane[SUP] 4 [/SUP], Oumaima Laazaazia[SUP] 1 [/SUP], Safaa Aqillouch[SUP] 1 [/SUP], Ahmed E Ogwell Ouma[SUP] 2 [/SUP], Mohammed Abdulaziz[SUP] 2 [/SUP], Merawi Aragaw[SUP] 2 [/SUP], Mosoka Papa Fallah[SUP] 2 [/SUP], Senga Sembuche[SUP] 2 [/SUP], Serge Batcho[SUP] 2 [/SUP], Patrick Kabwe[SUP] 2 [/SUP], Elizabeth Gonese[SUP] 2 [/SUP], Abdelhakim Ainahi[SUP] 5 [/SUP], M'hammed Sarih[SUP] 6 [/SUP], Jean Kaseya[SUP] #[/SUP][SUP] 2 [/SUP], Abderrahmane Maaroufi[SUP] #[/SUP][SUP] 1 [/SUP], Sayeh Ezzikouri[SUP] #[/SUP][SUP] 7 [/SUP]
Affiliations
- PMID: 39732651
- PMCID: PMC11682633
- DOI: 10.1186/s12879-024-10345-9
To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument. Adjusted seroprevalence of anti-RBD antibodies showed that participants who received two doses of ChAdOx1-S followed by a BBIBP-CorV booster had a seroprevalence rate of 99.68% (95% CI: 99.39-99.83%), while those who received a BNT162b2 booster had a rate of 99.67% (95% CI: 99.38-99.82%). Both rates were higher than those observed with other vaccination regimens. The evaluation of booster dose effects revealed significant differences in anti-RBD antibody levels across various vaccination regimens: two doses of BBIBP-CorV compared to three doses of BBIBP-CorV (P < 0.0001), two doses of BNT162b2 versus three doses of BNT162b2 (P = 0.023), two doses of ChAdOx1-S versus two doses of ChAdOx1-S with a BNT162b2 booster (P = 0.023), and two doses of BBIBP-CorV versus two doses of BBIBP-CorV with a BNT162b2 booster (P < 0.0001). However, no significant difference was found between two doses of ChAdOx1-S and three doses of ChAdOx1-S (P = 0.23). Participants with prior SARS-CoV-2 exposure who received two doses of ChAdOx1-S followed by either a BBIBP-CorV or BNT162b2 booster showed higher levels of anti-RBD IgG antibodies (P = 0.042 and P = 0.001, respectively). Interestingly, individuals with comorbidities who received the BNT162b2 booster dose exhibited a significantly stronger humoral response (P < 0.05). In conclusion, our findings highlight the effectiveness of the BNT162b2 booster dose in eliciting a strong immune response. The high seroprevalence rates achieved with both BNT162b2 and BBIBP-CorV boosters reflect the country's robust vaccination strategy.
Keywords: 3 doses, Vaccines; Anti-RBD; COVID-19; Humoral response; SARS-CoV-2; Seroprevalence.